IDiyas

For the Inventor, By the Inventor

Glostrup, Denmark

Jorgen Scheel-Kruger

USPTO Granted Patents = 10

Average Co-Inventor Count = 4.0

ph-index = 3

Forward Citations = 44(Granted Patents)


Location History:

  • Ballerup, DK (2002 - 2007)
  • Glostrup, DK (1994 - 2013)

Company Filing History:

goldMedal10 out of 206 
 
Neurosearch A/s
 patents

Years Active: 1994-2013

Loading Chart...
10 patents (USPTO):Explore Patents
1. 8410271 - Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2013-04-02),
2. 7989470 - 3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors (2011-08-02),
3. 7235548 - Compounds and their use as positive AMPA receptor modulators (2007-06-26),
4. 7199118 - Benzothiazine derivatives, their preparation and use (2007-04-03),
5. 6479491 - Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine d4 receptor antagonists (2002-11-12),
6. 6376673 - Piperidine derivatives as neurotransmitter re-uptake inhibitors (2002-04-23),
7. 6207662 - Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine D4 receptor antagonists (2001-03-27),
8. 5444070 - Phenyl substituted heterocyclic compounds (1995-08-22),
9. 5374636 - 2,3-trans-disubstituted tropane compounds which have useful (1994-12-20),
10. 5369113 - Certain 2,3-diphenyl-2-(1,2,4-oxadiazol-5-yl)tropanes useful as dopamide (1994-11-29),

Jorgen Scheel-Kruger: Innovator in Neurotransmitter Re-uptake Inhibitors

Introduction

Jorgen Scheel-Kruger is a notable inventor based in Glostrup, Denmark. With a remarkable portfolio consisting of 10 patents, he has made significant contributions to the field of pharmacology, specifically in the development of compounds that act as monoamine neurotransmitter re-uptake inhibitors.

Latest Patents

Among his latest innovations, two patents stand out:

1. **Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors** - This invention focuses on chromen-2-one derivatives that are useful in the treatment of neurological conditions. The compounds are intended for use in therapeutic methods and are included in pharmaceutical compositions.

2. **3,8-substituted 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors** - This novel invention highlights 8-aza-bicyclo[3.2.1]octane derivatives, which also serve as effective monoamine neurotransmitter re-uptake inhibitors.

Career Highlights

Jorgen Scheel-Kruger works at Neurosearch A/S, a company recognized for its research and development in the field of neuropharmacology. His innovative mindset and expertise have greatly influenced the advancement of therapeutic options for mental health conditions.

Collaborations

Throughout his career, Jorgen has collaborated with esteemed colleagues, including Peter Moldt and Dan Peters. These collaborations have fostered a rich environment for innovation and have contributed to the successful development of several groundbreaking patents.

Conclusion

Jorgen Scheel-Kruger exemplifies the spirit of innovation within the pharmaceutical industry. His ongoing research and patented inventions continue to pave the way for new treatments targeting neurotransmitter re-uptake mechanisms, thus improving the quality of life for many individuals suffering from neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…